Current status and future prospects of yellow fever vaccines

References

• Vainio J, Cutts F. Yellow fever. World Health Organization; Geneva: 1998
   Google Scholar
• Bazin H. Yellow fever vaccine. Vaccinations: A History. John Libbey Eurotext, Montrouge, France; 2011. p. 407-54
   Google Scholar
• World Health Organization. WHO-recommended standards for surveillance of selected vaccine preventable diseases. 2003
   Google Scholar
• Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. Trans R Soc Trop Med Hyg 2014;108:482-7
   PubMed Web of Science ®Google Scholar
• Burlaud-Gaillard J, Sellin C, Georgeault S, et al. Correlative scanning-transmission electron microscopy reveals that a chimeric flavivirus is released as individual particles in secretory vesicles. PLoS One 2014;9:e93573
   PubMed Web of Science ®Google Scholar
• Monath TP, Gershman M, Staples JE, Barrett ADT. Yellow fever vaccine. In: Plotkin S, editor. Vaccines. Sixth edition. Elsevier, Inc; 2013. p. 870-15
   Google Scholar
• Jentes ES, Poumerol G, Gershman MD, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO working group on geographic risk for yellow fever. Lancet Infect Dis 2011;11:622-32
   PubMed Web of Science ®Google Scholar
• Stokes A, Bauer JH, Hudson NP. Experimental transmission of yellow fever to laboratory animals. Am J Trop Med Hyg 1928;1:103-64
   Google Scholar
• Theiler M. Susceptibility of white mice to the virus of yellow fever. Science; New York, NY: 1930. p. 71-367
   Google Scholar
• Theiler M. Neutralization tests with immune yellow fever sera and a strain of yellow fever virus adapted to mice. Ann Trop Med Parasitol 1931;25:69-77
   Google Scholar
• Sellards AW, Hindle E. The preservation of yellow fever virus. Br Med J 1928;1:713-14
   PubMedGoogle Scholar
• Theiler M. Studies on the action of yellow fever virus in mice. Ann trop Med Parasit 1930;24:249-72
   Google Scholar
• Durieux C. Preparation of yellow fever vaccine at the Institut Pasteur, Dakar. In: Smithburn KC, Duriex C, Koerber R, et al. editors. YF Vaccination Monograph Series. World Health Organization; Geneva: 1956. p. 31
   Google Scholar
• Lloyd W, Penna HA. Studies on the pathogenesis of neurotropic yellow fever virus in Macacus rhesus. Am J Trop Med Hyg 1933;8:1-45
   Google Scholar
• Ni H, Ryman KD, Wang H, et al. Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants. J Virol 2000;74:2903-6
   PubMed Web of Science ®Google Scholar
• Sawyer WA, Kitchen SF, Lloyd W. Vaccination against yellow fever with immune serum and virus fixed for mice. J Experimen Med 1932;55:945-69
   PubMedGoogle Scholar
• Stones PB, Macnamarra FN. Encephalitis following neurotropic yellow fever vaccine administered by scarification in Nigeria: epidemiological and laboratory studies. Trans R Soc Trop Med Hyg 1955;49:176-86
   PubMedGoogle Scholar
• Wang E, Ryman KD, Jennings AD, et al. Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. J Gen Virol 1995;76(Pt 11):2749-55
   PubMed Web of Science ®Google Scholar
• Theiler M, Smith HH. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Experimen Med 1937;65:767-86
   PubMedGoogle Scholar
• Whitman L. Failure of Aedes aegypti to transmit yellow fever cultured virus (17D). Am J Trop Med 2015;19:19-26
   Google Scholar
• Miller BR, Adkins D. Biological characterization of plaque-size variants of yellow fever virus in mosquitoes and mice. Acta Virol 1988;32:227-34
   PubMed Web of Science ®Google Scholar
• United Nations Relief and Rehabilitation Administration. Report to the UNRAA expert commission on quarantine: Dakar yellow-fever vaccine. 2014. p. 618-37
   Google Scholar
• Stuart G. The problem of mass vaccination against yellow fever. World Health Organization; Geneva: 1953. p. 1-13
   Google Scholar
• World Health Organization. Standards for the manufacture and control of yellow fever vaccine. World Health Organ Epidemiol Bull. Volume 1 World Health Organization; Geneva: 1945. p. 365-70
   Google Scholar
• Barrett AD, Teuwen DE. Yellow fever vaccine–how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 2009;21:308-13
   PubMed Web of Science ®Google Scholar
• Garske T, Van Kerkhove MD, Yactayo S, et al. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med 2014;11:e1001638
   PubMed Web of Science ®Google Scholar
• GAVI. Yellow fever supply and procurement roadmap. Available from: http://www.gavi.org/library/gavi-documents/supply-procurement/yellow-fever-roadmap-public-summary/ [Last accessed 18 June 2015]
   Google Scholar
• Roukens AH, Vossen AC, Bredenbeek PJ, et al. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One 2008;3:e1993
   PubMed Web of Science ®Google Scholar
• Roukens AH, Vossen AC, van Dissel JT, Visser LG. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine 2009;27:2408-9
   PubMed Web of Science ®Google Scholar
• WHO Expert Committee on Biological Standardization. Recommendations to assure the quality, safety, and efficacy of live attenuated yellow fever vaccines. Volume 978 World Health Organization Technical Report Series; Geneva: 2013. p. 241-314
   Google Scholar
• Bres P, Koch M. Production and testing of the WHO yellow fever virus primary seed lot 213-77 and reference batch 168-73. In: Standardization WECoB, editor. World health organization technical report series. Volume 36 World Health Organization; Geneva: 1987. p. 113-41
   Google Scholar
• Hahn CS, Dalrymple JM, Strauss JH, Rice CM. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci USA 1987;84:2019-23
   PubMed Web of Science ®Google Scholar
• dos Santos CN, Post PR, Carvalho R, et al. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res 1995;35:35-41
   PubMed Web of Science ®Google Scholar
• Stock NK, Boschetti N, Herzog C, et al. The phylogeny of yellow fever virus 17D vaccines. Vaccine 2012;30:989-94
   PubMed Web of Science ®Google Scholar
• Catteau A. Dengue virus M protein contains a proapoptotic sequence referred to as ApoptoM. J Gen Virol 2003;84:2781-93
   PubMed Web of Science ®Google Scholar
• Lee E, Lobigs M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol 2008;82:6024-33
   PubMed Web of Science ®Google Scholar
• Muñoz-Jordán JL, Laurent-Rolle M, Ashour J, et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 2005;79:8004-13
   PubMed Web of Science ®Google Scholar
• McElroy KL, Tsetsarkin KA, Vanlandingham DL, Higgs S. Manipulation of the yellow fever virus non-structural genes 2A and 4B and the 3’non-coding region to evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut. Am J Trop Med Hyg 2006;75:1158-64
   PubMed Web of Science ®Google Scholar
• Huang Y-JS, Nuckols JT, Horne KM, et al. Mutagenesis analysis of T380R mutation in the envelope protein of yellow fever virus. Virol J 2014;11:1-4
   PubMed Web of Science ®Google Scholar
• Minor PD. Neurovirulence tests of three 17D yellow fever vaccine strains. Biologicals 2011;39:167-70
   PubMed Web of Science ®Google Scholar
• Lang J, Zuckerman J, Clarke P, et al. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg 1999;60:1045-50
   PubMed Web of Science ®Google Scholar
• Belmusto-Worn VE, Sanchez JL, McCarthy K, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 2005;72:189-97
   PubMed Web of Science ®Google Scholar
• Camacho LAB. Freire MdS, Leal MdLF, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004;38:671-8
   PubMed Web of Science ®Google Scholar
• Camacho LAB, Aguiar SG, Freire MdS, et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica 2005;39:413-20
   PubMed Web of Science ®Google Scholar
• Pfister M, Kürsteiner O, Hilfiker H, et al. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 2005;72:339-46
   PubMed Web of Science ®Google Scholar
• Ripoll C, Ponce A, Wilson MM, et al. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina. Hum Vaccin 2014;4:121-6
   Web of Science ®Google Scholar
• Rice CM, Grakoui A, Galler R, Chambers TJ. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. N Biolog 1989;1:285-96
   PubMedGoogle Scholar
• Bonaldo MC, Garratt RC, Marchevsky RS, et al. Attenuation of Recombinant Yellow Fever 17D Viruses Expressing Foreign Protein Epitopes at the Surface. J Virol 2005;79:8602-13
   PubMed Web of Science ®Google Scholar
• Nogueira RT, Nogueira AR, Pereira MCS, et al. Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi. PLoS One 2013;8:e59347
   PubMed Web of Science ®Google Scholar
• Bonaldo MC, Martins MÂ, Rudersdorf R, et al. Recombinant Yellow Fever Vaccine Virus 17D Expressing Simian Immunodeficiency Virus SIVmac239 Gag Induces SIV-Specific CD8+ T-Cell Responses in Rhesus Macaques. J Virol 2010;84:3699-706
   PubMed Web of Science ®Google Scholar
• Bredenbeek PJ, Molenkamp R, Spaan WJM, et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006;345:299-304
   PubMed Web of Science ®Google Scholar
• Bray M, Lai CJ. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Nat Acad Sci USA 1991;88:10342-6
   PubMed Web of Science ®Google Scholar
• Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011;29:7229-41
   PubMed Web of Science ®Google Scholar
• Appaiahgari MB, Vrati S. IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines 2010;9:1371-84
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase III, randomised, observer-masked, placebo-controlled trial. Lancet 2014;384:1358-65
   PubMed Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-García JL, et al. Efficacy of a tetravalent dengue vaccine in children in latin America. N Eng J Med 2015;372:113-23
   PubMed Web of Science ®Google Scholar
• Monath TP, Liu J, Kanesa-Thasan N, et al. A live, attenuated recombinant West Nile virus vaccine. Proc Nat Acad Sci USA 2006;103:6694-9
   PubMed Web of Science ®Google Scholar
• Biedenbender R, Bevilacqua J, Gregg AM, et al. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infec Dis 2011;203:75-84
   PubMed Web of Science ®Google Scholar
• Rumyantsev AA, Goncalvez AP, Giel-Moloney M, et al. Single-dose vaccine against tick-borne encephalitis. Proc Nat Acad Sci 2013;110:13103-8
   PubMed Web of Science ®Google Scholar
• DeSilva M, Sharma A, Staples E, et al. Notes from the field: fatal yellow fever vaccine-associated viscerotropic disease–Oregon, September 2014. MMWR Morb Mortal Week Report 2015;64:279-81
   PubMed Web of Science ®Google Scholar
• Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012;30:5038-58
   PubMed Web of Science ®Google Scholar
• Whittembury A, Ramirez G, Hernández H, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009;27:5974-81
   PubMed Web of Science ®Google Scholar
• Monath TP, Cetron MS, McCarthy K, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005;1:207-14
   PubMed Web of Science ®Google Scholar
• Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the advisory committee on immunization practices (ACIP). In: Shaw F, editor, Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention (CDC), Atlanta; 2010;59:1-27
   Google Scholar
• Meier KC, Gardner CL, Khoretonenko MV, et al. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 2009;5:e1000614
   PubMed Web of Science ®Google Scholar
• Erickson AK, Pfeiffer JK. Dynamic Viral Dissemination in Mice Infected with Yellow Fever Virus Strain 17D. J Virol 2013;87:12392-7
   PubMed Web of Science ®Google Scholar
• Roukens AH, Soonawala D, Joosten SA, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS One 2011;6:e27753-6
   PubMed Web of Science ®Google Scholar
• Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine–associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infec Dis 2008;198:500-7
   PubMed Web of Science ®Google Scholar
• Monath TP, Lee CK, Julander JG, et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 2010;28:3827-40
   PubMed Web of Science ®Google Scholar
• Monath TP, Fowler E, Johnson CT, et al. An inactivated cell-culture vaccine against yellow fever. N Eng J Med 2011;364:1326-33
   PubMed Web of Science ®Google Scholar
• Gaspar LP, Mendes YS, Yamamura AMY, et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 2008;150:57-62
   PubMed Web of Science ®Google Scholar
• Pereira RC, Silva ANMR, Souza MCO, et al. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures. Vaccine 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Pincus S, Mason PW, Konishi E, et al. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 1992;187:290-7
   PubMed Web of Science ®Google Scholar
• Schäfer B, Holzer GW, Joachimsthaler A, et al. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS One 2011;6:e24505
   PubMed Web of Science ®Google Scholar
• Maciel M, Cruz FdSP, Cordeiro MT, et al. A DNA vaccine against yellow fever virus: development and evaluation. PLoS Negl Trop Dis 2015;9:e0003693
   PubMed Web of Science ®Google Scholar
• Findlay GM, Clarke LP. Reconversion of the neurotropic into the viscerotropic strain of yellow fever virus in rhesus monkeys. Trans R Soc Trop Med Hyg 1935;28:579-600
   Google Scholar
• Soper FL, Smith HH. Vaccination with virus 17D in the control of jungle yellow fever in Brazil. In: Transactions of the Third International Congress of Tropical Medicine and Malaria. C.A. Spin & Zoon N.V., Holland; 1938:295-313
   Google Scholar
• Freire MS, Mann GF, Marchevsky RS, et al. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity. Vaccine 2005;23:2501-12
   PubMed Web of Science ®Google Scholar
• Beasley DWC, Morin M, Lamb AR, et al. Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes. Virus Res 2013;1-5
   Web of Science ®Google Scholar
• Neverov A, Chumakov K. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. Proc Natl Acad Sci USA 2010;107:20063-8
   PubMed Web of Science ®Google Scholar
• Andino R, Domingo E. Viral quasispecies. Virology 2015;479-480C:46-51
   Web of Science ®Google Scholar
• Victoria JG, Wang C, Jones MS, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 2010;84:6033-40
   PubMed Web of Science ®Google Scholar
• Beck A, Tesh RB, Wood TG, et al. Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing. J Infec Dis 2014;209:334-44
   PubMed Web of Science ®Google Scholar
• Assembly WH. International health regulations (2005). World Health Organization; Geneva: 2006
   Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2013 – conclusions and recommendations. Wkly Epidemiol Rec 2013;88:201-6
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention(CDC). Advisory committee on immunization practices (ACIP). Summary Report 26 February 2015, Atlanta, GA. 2015. p. 1-72
   Google Scholar
• Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013;89:434-44
   PubMed Web of Science ®Google Scholar
• Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Inter health 1999;4:867-71
   PubMed Web of Science ®Google Scholar
• Mudd PA, Piaskowski SM, Neves PCC, et al. The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques–implications for recombinant vaccine design. Immunogenetics 2010;62:593-600
   PubMed Web of Science ®Google Scholar
• Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 2011;29:6008-16
   PubMed Web of Science ®Google Scholar
• Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2008;10:116-25
   PubMed Web of Science ®Google Scholar
• Li S, Rouphael N, Duraisingham S, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 2014;15:195-204
   PubMed Web of Science ®Google Scholar
• Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Experim Med 2008;205:3119-31
   PubMed Web of Science ®Google Scholar
• Akondy RS, Johnson PLF, Nakaya HI, et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc Nat Acad Sci 2015;112:3050-5
   PubMed Web of Science ®Google Scholar
• Campi-Azevedo AC, de Araújo-Porto LP, Luiza-Silva M, et al. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PLoS One 2012;7:e49828
   PubMed Web of Science ®Google Scholar
• Neves PCC, Rudersdorf RA, Galler R, et al. CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-γ at 5-7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses. Vaccine 2010;28:8183-8
   PubMed Web of Science ®Google Scholar
• Neves PCC, Santos JR, Tubarão LN, et al. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses. PLoS One 2013;8:e81953
   PubMed Web of Science ®Google Scholar